Inland Northwest Research | Spokane, WA

Research site

(Unclaimed)

Location

610 South Sherman Street, Suite 20, Spokane, Washington, United States of America

Site insights

Top conditions

Top treatments

ABBV-951

TD-9855

Carbidopa

Levodopa

Buntanetap

BIIB122

SEP-363856

Neflamapimod

NE3107

ABBV-0805

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

9 of 38 total trials

A Study of TAK-341 in Treatment of Multiple System Atrophy

The main aim is to see how TAK-341 works after 52 weeks in participants with multiple system atrophy as measured by the Unified Multiple System Atrop...

Enrolling

Multiple System Atrophy

Drug: Placebo

Drug: TAK-341

A Study to Assess the Safety of BIIB122 Tablets and if it Can Slow the Worsening of Early-Stage Parkinson's Disease in Participants Between the Ages of 30 and 80 (LUMA)

In this study, researchers will learn more about a study drug called BIIB122 in participants with early-stage Parkinson's disease (PD). In this study...

Enrolling

Parkinson Disease

Drug: BIIB122-Matching Placebo

Drug: BIIB122

A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease (PADOVA)

This is a multicenter, randomized, double-blind, placebo-controlled study that will evaluate the efficacy and safety of intravenous (IV) prasinezumab...

Active, not recruiting

Parkinsons Disease

Drug: Prasinezumab

Drug: Placebo

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BIIB094 in Adults With Parkinson's Disease (REASON)

The primary objective of this study is to evaluate the safety and tolerability of single and multiple doses of BIIB094 administered via intrathecal (...

Active, not recruiting

Parkinson's Disease

Drug: Placebo

Drug: BIIB094

Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD (ACTIVATE)

The purpose of this randomized, double-blind, placebo-controlled study is to assess the efficacy of BIA 28-6156 over placebo in delaying clinical mea...

Enrolling

Parkinson's Disease

Drug: Placebo

Drug: BIA 28-6156 60 mg

Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure Of Continuous Subcutaneous Infusion of ABBV-951 In Adult Participants With Parkinson's Disease

Parkinson's disease (PD) is a neurological condition, which affects the brain. PD gets worse over time, but how quickly it progresses varies a lot fr...

Active, not recruiting

Parkinson's Disease (PD)

Drug: ABBV-951

GENERATION HD2. A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants With Prodromal and Early Manifest Huntington's Disease.

This study will evaluate the safety, biomarkers, and efficacy of tominersen compared with placebo in participants with prodromal and early manifest H...

Enrolling

Huntington Disease

Drug: Tominersen 60 mg

Drug: Placebo

STEM-Parkinson's Disease

This is a double-blinded, controlled, randomized clinical trial (RCT) to establish the safety and efficacy of a non-invasive neuromodulation device f...

Enrolling

Parkinson Disease

Parkinson's Disease and Parkinsonism

Device: Non-invasive brainstem stimulation

Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson's Disease

Parkinson's disease (PD) is a neurological condition, which affects the brain. PD gets worse over time, but how quickly it progresses varies a lot fr...

Active, not recruiting

Parkinson's Disease (PD)

Drug: ABBV-951